€573.40
3.54% yesterday
Brüssel, Aug 18, 05:36 pm CET
ISIN
NL0010832176
Symbol
ARGX

arGEN-X Stock price

€573.40
+81.40 16.54% 1M
-40.40 6.58% 6M
-26.60 4.43% YTD
+99.10 20.89% 1Y
+198.50 52.95% 3Y
+371.80 184.42% 5Y
+563.14 5,488.69% 10Y
+565.50 7,158.23% 20Y
Brüssel, Closing price Mon, Aug 18 2025
+19.60 3.54%
ISIN
NL0010832176
Symbol
ARGX
Industry

Key metrics

Basic
Market capitalization
€34.1b
Enterprise Value
€30.7b
Net debt
positive
Cash
€3.4b
Shares outstanding
61.2m
Valuation (TTM | estimate)
P/E
33.2 | 55.4
P/S
13.1 | 10.8
EV/Sales
11.8 | 9.7
EV/FCF
116.6
P/B
6.5
Financial Health
Equity Ratio
88.7%
Return on Equity
15.2%
ROCE
7.6%
ROIC
33.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
€2.6b | €3.2b
EBITDA
€417.6m | €691.0m
EBIT
€398.7m | €657.1m
Net Income
€1.1b | €611.8m
Free Cash Flow
€263.8m
Growth (TTM | estimate)
Revenue
- | 69.1%
EBITDA
- | 17,461.2%
EBIT
- | 5,589.3%
Net Income
- | -14.0%
Free Cash Flow
194.9%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
16.0% | 21.8%
EBIT
15.3%
Net
42.0% | 19.3%
Free Cash Flow
10.1%
More
EPS
€16.7
FCF per Share
€4.3
Short interest
-
Employees
2k
Rev per Employee
€1.2m
Show more

Is arGEN-X a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

arGEN-X Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a arGEN-X forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a arGEN-X forecast:

Buy
92%
Hold
8%

Financial data from arGEN-X

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,607 2,607
-
100%
- Direct Costs 276 276
-
11%
2,330 2,330
-
89%
- Selling and Administrative Expenses 995 995
-
38%
- Research and Development Expense 1,000 1,000
-
38%
418 418
-
16%
- Depreciation and Amortization 19 19
91% 91%
1%
EBIT (Operating Income) EBIT 399 399
-
15%
Net Profit 1,094 1,094
-
42%

In millions EUR.

Don't miss a Thing! We will send you all news about arGEN-X directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today